the product in the database has an inactive status
indications:
Open angle glaucoma and intraocular hypertension.
Composition:
1 ml drops contains 50 μg latanoprost.
Action:
Prostaglandin analog F2α, a selective prostanoid agonist of FP receptors. It reduces intraocular pressure by increasing the outflow of aqueous humor. It increases the choroid-scleral flow and reduces the flow resistance. The drug has no significant effect on the production of aqueous humor, does not affect the blood-liquid barrier. The reduction in intraocular pressure occurs about 3-4 hours after application, the maximum effectiveness is achieved after 8-12 h, the effect is maintained for at least 24 h. After administration to the conjunctival sac, the preparation is absorbed through the cornea and is hydrolyzed to the biologically active acid latanoprost. The maximum concentration of the drug in aqueous humor occurs approximately 2 hours after administration. It is distributed mainly in the anterior chamber, in the conjunctiva and the eyelids, only minimal amounts reach the chamber of the posterior eye. Metabolism occurs mainly in the liver. T0,5 in plasma is 17 min. Inactive metabolites are mainly excreted in the urine.
Contraindications:
Hypersensitivity to latanoprost or to any of the ingredients.
Precautions:
Caution should be exercised when treating patients with closed-angle, chronic glaucoma with closed-angle glaucoma, open-angle glaucoma in patients with pseudophakia, pigmented glaucoma, inflammatory glaucoma, neovascular glaucoma, congenital glaucoma and inflammation of the eye - limited clinical experience. Caution should be exercised in perioperative patients after cataract extraction and in patients with aphasia, pseudophakia with discontinuous posterior capsule or lenses implanted in the anterior chamber of the eye or in patients at risk for cystic macular edema. Carefully used in patients with a tendency to develop iritis or uveitis. Caution should be exercised in patients with asthma, as it may intensify and / or shortness of breath. The safety and efficacy of the preparation in adolescent children have not been established - use is not recommended.
Pregnancy and lactation:
The preparation should not be used during pregnancy. Latanoprost and its metabolites can penetrate into breast milk. Do not use the drug in breastfeeding women, or stop feeding.
Side effects:
Very common (≥1 / 10): increased pigmentation of the iris (most commonly in people with mixed iris colouration eg: blue-brown, gray-brown, yellow-brown and green-brown), eye irritation (burning, roughness, pruritus, prickling) , feeling of the presence of a foreign body), mild to moderate conjunctival hyperemia, changes in the appearance of eyelashes and follicular hair on the eyelid (lengthening, thickening, darkening and increasing the amount, observed mostly in the Japanese population). Common (≥1 / 100, to <1/10): transient punctate epithelial defects (most often without symptoms), eyelid inflammation, eye pain. Uncommon (≥1 / 1000, up to <1/100): eyelid edema, dry eye syndrome, keratitis, visual acuity disorders, conjunctivitis; skin rash. Rare (≥1 / 10000, up to <1/1000): iritis or uveitis, macular edema, symptomatic swelling and corneal defects, periorbital edema, changes in the direction of eyelash growth (this may cause eye irritation), appearance of a double order eyelash on the holes of the thyroid glands; local skin reactions on the eyelids, darkening of the eyelid skin; asthma, exacerbation of asthma, shortness of breath. Very rare (<1 / 10,000): worsening of angina pectoris in patients with pre-existing disease; pain in the chest. In addition, pain and dizziness were observed; palpitations; muscle and joint pain.
Dosage:
Adults: 1 drop into the conjunctival sac of the affected eye (eyes) once a day, preferably in the evening. Do not administer the preparation more than once a day.Immediately after instillation, it is recommended to compress the conjunctival sac in the medial part of the eyelid angle for one minute. If the patient uses more than one eye medicine, each of these medicines should be administered with a 5-minute break.
(C)
